Articles

For all three compounds, the evidence chain breaks at the species boundary. A 2026 UCLA scoping review of 565 studies across six unapproved peptides found that BPC-157, TB-500, and GHK-Cu have no completed human RCTs measuring body composition or athletic recovery as primary endpoints. Preclinical mechanisms are quantified; human performance outcomes are not.

The 2026 Demirtaş critical review in International Journal of Molecular Sciences (IJMS 27(18):8344) appraises the preclinical IRI evidence for BPC-157 as mechanistically coherent but structurally limited: consistent rodent results across oxidative stress, endothelial, and apoptotic endpoints, yet concentrated in a single research group, delivered exclusively via parenteral routes, and without a validated pharmacokinetic bridge to human performance contexts.

MK-677 (ibutamoren) produces a statistically significant but modest lean-mass gain of approximately 1.6 kg above placebo over 12 months in the only controlled human trial. It simultaneously raises fasting glucose, reduces insulin sensitivity, and generated a congestive heart failure signal that terminated a separate elderly-population trial. The lean-mass benefit is real but narrow, and the cardiometabolic cost is not negligible.

Retatrutide's glucagon receptor (GCGR) component creates a dual-edged lean-mass signal: it drives hepatic amino acid catabolism via urea-cycle upregulation — a direct lean-mass liability — while simultaneously increasing energy expenditure through fat oxidation, reducing substrate pressure on muscle protein. Resistance training resolves this tension by redirecting circulating amino acids toward myofibrillar synthesis rather than hepatic gluconeogenesis.

Mostly animal data, with one narrow human exception. A 2026 UCLA Health review of 565 studies across six unapproved peptides concluded that human evidence is sparse and marketing claims substantially outpace the clinical record. MK-677 has the strongest human dataset, but its one meaningful RCT enrolled elderly adults rather than athletes, and total fat mass rose alongside lean-mass gains.

The 2026 systems medicine review of semaglutide (Tandfonline, Expert Review of Clinical Pharmacology) integrates proteomic and metabolomic datasets with major RCT outcomes to show that semaglutide reconfigures substrate flux across liver, skeletal muscle, and adipose tissue simultaneously. These molecular shifts begin 4 to 8 weeks before measurable weight loss, creating a distinct periodization window for diet and training intervention.

A 2026 critical review in International Journal of Molecular Sciences (IJMS 27(18):8344) evaluates preclinical evidence for BPC-157 in rodent ischemia–reperfusion injury. The review identifies four converging protective axes — oxidative stress attenuation, endothelial NO modulation, Src–FAK kinase signaling, and vascular remodeling — all documented exclusively in rodent models with no validated human translation as of 2026.

No controlled human trial has measured BPC-157's effect on injury recovery, training performance, or body composition in resistance-trained individuals. The entire efficacy database is preclinical — rodent and cell-culture models. A 2026 PMC report on gray-market peptide use (Hailu et al., PMC13355462) flags rising self-administration alongside serious quality and safety concerns that outpace the human evidence.

A 2025 meta-analysis by Hays et al found that TRE combined with exercise produced a significant fat-mass reduction and improved HOMA-IR versus exercise-matched controls, while fat-free mass remained statistically unchanged. The benefit is real but modest in absolute terms, and protein intake is the primary moderating variable.

The 2025 Sikiric–Józwiak commentary exchange in Pharmaceuticals resolves a standing BPC-157 paradox: the peptide increases or decreases nitric oxide and eNOS expression depending on injury context, yet invariably suppresses free radical formation. This context-dependence means BPC-157's NO-driven perfusion and repair effects are state-dependent responses — not fixed pharmacological outputs — calibrated to local redox conditions.

Acute endurance exercise reliably elevates circulating humanin and MOTS-c within minutes of exertion; resistance exercise does not produce the same acute plasma response. Across pooled human studies, exercise-driven MOTS-c rises co-occur with AMPK activation, improved GLUT4 translocation, and reduced HOMA-IR, while humanin increases correlate with attenuated oxidative stress markers — providing a mechanistic bridge between training load and insulin-sensitivity gains.

Yes — a 2026 isotope-tracer clinical study confirms that orally ingested lysine is catabolised to alpha-aminoadipic acid (2-AAA) within 30 minutes, peaking at roughly 2 hours post-ingestion. Lysine also stimulates a rise in unlabelled, endogenously produced 2-AAA — suggesting the amino acid load triggers a broader metabolic signal beyond simple catabolism, with documented links to beta-cell function and insulin sensitivity.